Drugs Health Pharma

Eli Lilly’s Zepbound resolves sleep apnea in more than half of trial patients 

Tirzepatide, an obesity drug of  Eli Lilly and Company, has helped resolve moderate-to-severe obstructive sleep apnea in 52.% of adult patients in two.

Read More
Drugs Health Pharma

AstraZeneca’s trial breast cancer drug fails to meet primary goals

AstraZeneca’s end-stage experimental trial to treat a certain type of breast cancer failed to meet its dual primary goals, according to a statement.

Read More
Drugs Health Pharma

Takeda’s trials for epilepsy treatment fail to meet primary seizure goals

Takeda Pharmaceutical Company’s two trials for treating epilepsy did not meet its primary goals of seizure frequency, the Japanese company announced.

Read More
Drugs Health Pharma

Merck’s vaccine for pneumococcal disease gets FDA’s green light

The US Food and Drug Administration has given the green light to Merck’s vaccine to protect adults against the different types of bacteria.

Read More
Drugs Health Pharma

FDA gives nod for AstraZeneca’s Imfinzi to treat endometrial cancer

The US Food and Drug Administration has approved AstraZeneca’s combination therapy, Imfinzi, for adult patients with endometrial cancer, according to a company statement.

Read More
Drugs Health Pharma

AstraZeneca’s trial drug for mantle cell lymphoma raises survival rate

AstraZeneca’s mantle cell lymphoma combination rug, Calquence, reduced the risk of disease progression or death by up to 27%, according to a company.

Read More
Drugs Health Pharma

Pfizer’s blood cancer trial data shows survival of more than 2 years 

Pfizer Inc.,’s investigational drug for blood cancer, Elrexfio, has shown an overall survival rate of 24.6 months in a single-arm trial, according to.

Read More
Drugs Health Pharma

FDA approves AstraZeneca’s type-2 diabetes drug in US market

AstraZeneca’s oral drug to treat type-2 diabetes in patients aged 10 years and above has got approval from the US drug regulator, according.

Read More
Drugs Health Pharma

Pfizer’s Duchenne muscular dystrophy trial fails to meet primary goal

Pfizer’s investigations on gene therapy for patients with Duchenne muscular dystrophy failed to meet its primary goals, according to a company statement.

Read More
Drugs Health Pharma

GSK’s blood cancer test drug halves risk of disease progression: Data 

British drugmaker, GSK Plc.’s multiple myeloma drug, Blenrep, reduced the risk of disease progression or death by about 50% when compared to a.

Read More
X